Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

Bibliographic Details
Main Authors:	Mihaylova, B, Armitage, J, Briggs, A, Gray, A, Parish, S, Collins, R, Collaborati, H
Format:	Conference item
Published:	2005

Similar Items

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
by: Mihaylova, B, et al.
Published: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
by: Mihaylova, B, et al.
Published: (2006)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
by: Armitage, J, et al.
Published: (2009)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
by: Heart Protection Study Collaborative Group
Published: (2002)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
by: Bulbulia, R, et al.
Published: (2011)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
by: Group, H
Published: (2005)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
by: Heart Protection Study Collaborative Group
Published: (2007)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
by: Collins, R, et al.
Published: (2004)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
by: Collins, R, et al.
Published: (2002)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
by: Emberson, JR, et al.
Published: (2007)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
by: Collins, R, et al.
Published: (2003)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
by: Mihaylova, B, et al.
Published: (2009)

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.
by: Harris, M, et al.
Published: (1995)

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
by: Keech, A, et al.
Published: (1996)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
by: Armitage, J, et al.
Published: (2010)

Economic evaluation of the Heart Protection Study
by: Briggs, A, et al.
Published: (2003)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
by: Hopewell, J, et al.
Published: (2009)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
by: Bulbulia, R, et al.
Published: (2008)

Safety of long-term simvastatin discontinuation Reply
by: Bulbulia, R, et al.
Published: (2012)

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
by: Mitropoulos, K, et al.
Published: (1997)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
by: Kent, S, et al.
Published: (2016)

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2013)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
by: Hopewell, JC, et al.
Published: (2020)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
by: Wardle, J, et al.
Published: (1996)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
by: Parish, S, et al.
Published: (2010)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
by: Mihaylova, B, et al.
Published: (2012)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
by: Baigent, C, et al.
Published: (2011)

C-reactive protein in the Heart Protection Study Reply
by: Emberson, J, et al.
Published: (2011)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
by: Wardle, J, et al.
Published: (1996)

Aspirin for primary prevention of vascular disease in people with diabetes.
by: Haynes, R, et al.
Published: (2009)

RPK 536 - PERANCANGAN PENGANGKUTAN FEB 01.
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (2001)

RPK 536 – Transportation Planning - Jun 2013
by: PPPBP, Pusat Pengajian Perumahan Bangunan Dan Perancangan
Published: (2013)

RPK 536 - PERANCANGAN PENGANGKUTAN APRIL 1993.
by: PPPB, Pusat Pengajian Perumahan Bangunan & Perancangan (School of Houusing, Building & Planning)
Published: (1993)

RMK536 - PERANCANGAN PENGANKUTAN APRIL 1995
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (1995)

RPK536 - PERANCANGAN PENGANGKUTAN FEBRUARI 1998
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (1998)

RPK 536 — Perancangan Pengangkutan - Februari 2000
by: PPPBP, Pusat Pengajian Perumahan Bangunan Dan Perancangan
Published: (2000)

CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
by: Chen, Z, et al.
Published: (1997)